BRPI0920459B1 - Compostos antagonistas de receptor de mineralocorticoide, composição farmacêutica e método in vitro de inibição da atividade do receptor de mineralocorticoide - Google Patents
Compostos antagonistas de receptor de mineralocorticoide, composição farmacêutica e método in vitro de inibição da atividade do receptor de mineralocorticoide Download PDFInfo
- Publication number
- BRPI0920459B1 BRPI0920459B1 BRPI0920459-8A BRPI0920459A BRPI0920459B1 BR PI0920459 B1 BRPI0920459 B1 BR PI0920459B1 BR PI0920459 A BRPI0920459 A BR PI0920459A BR PI0920459 B1 BRPI0920459 B1 BR PI0920459B1
- Authority
- BR
- Brazil
- Prior art keywords
- group
- phenyl
- methyl
- compound
- hydroxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 121
- 238000000034 method Methods 0.000 title claims description 24
- 230000000694 effects Effects 0.000 title claims description 21
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 title claims description 10
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 title claims description 10
- 238000000338 in vitro Methods 0.000 title claims description 6
- 230000002401 inhibitory effect Effects 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 229940083712 aldosterone antagonist Drugs 0.000 title description 8
- 125000005843 halogen group Chemical group 0.000 claims abstract description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 41
- -1 2-hydroxy-1-methylpropyl group Chemical group 0.000 claims description 26
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 6
- WSRMVIRQHUZSGA-CABCVRRESA-N 5-(2-chloro-4-fluorophenyl)-1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)Cl)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 WSRMVIRQHUZSGA-CABCVRRESA-N 0.000 claims description 5
- NHVGLTBLUNAPQE-CABCVRRESA-N 5-[4-chloro-2-(trifluoromethyl)phenyl]-1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(Cl)=CC=2)C(F)(F)F)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 NHVGLTBLUNAPQE-CABCVRRESA-N 0.000 claims description 5
- RKOXRANVRDCFQL-CABCVRRESA-N 5-[4-fluoro-2-(trifluoromethyl)phenyl]-1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)C(F)(F)F)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 RKOXRANVRDCFQL-CABCVRRESA-N 0.000 claims description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 5
- AAJDXRXNKJLUSF-CVEARBPZSA-N 1-[(2r,3s)-3-hydroxybutan-2-yl]-4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC=CC=2)C(F)(F)F)N([C@H](C)[C@@H](O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 AAJDXRXNKJLUSF-CVEARBPZSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- AAJDXRXNKJLUSF-UHFFFAOYSA-N 1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC=CC=2)C(F)(F)F)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 AAJDXRXNKJLUSF-UHFFFAOYSA-N 0.000 claims description 3
- WSRMVIRQHUZSGA-UHFFFAOYSA-N 5-(2-chloro-4-fluorophenyl)-1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)Cl)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 WSRMVIRQHUZSGA-UHFFFAOYSA-N 0.000 claims description 3
- NHVGLTBLUNAPQE-UHFFFAOYSA-N 5-[4-chloro-2-(trifluoromethyl)phenyl]-1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(Cl)=CC=2)C(F)(F)F)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 NHVGLTBLUNAPQE-UHFFFAOYSA-N 0.000 claims description 3
- RKOXRANVRDCFQL-UHFFFAOYSA-N 5-[4-fluoro-2-(trifluoromethyl)phenyl]-1-(3-hydroxybutan-2-yl)-4-methyl-n-(4-methylsulfonylphenyl)pyrrole-3-carboxamide Chemical compound CC1=C(C=2C(=CC(F)=CC=2)C(F)(F)F)N(C(C)C(O)C)C=C1C(=O)NC1=CC=C(S(C)(=O)=O)C=C1 RKOXRANVRDCFQL-UHFFFAOYSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 6
- 125000000217 alkyl group Chemical group 0.000 abstract description 5
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 63
- 239000000243 solution Substances 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000002904 solvent Substances 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 25
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 206010020772 Hypertension Diseases 0.000 description 17
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 15
- 208000033679 diabetic kidney disease Diseases 0.000 description 15
- 208000017169 kidney disease Diseases 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 14
- 206010019280 Heart failures Diseases 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 13
- 238000004296 chiral HPLC Methods 0.000 description 13
- GCFHZZWXZLABBL-UHFFFAOYSA-N ethanol;hexane Chemical compound CCO.CCCCCC GCFHZZWXZLABBL-UHFFFAOYSA-N 0.000 description 13
- 230000014759 maintenance of location Effects 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 12
- 206010007559 Cardiac failure congestive Diseases 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 238000004896 high resolution mass spectrometry Methods 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 229940126585 therapeutic drug Drugs 0.000 description 10
- 206010016654 Fibrosis Diseases 0.000 description 9
- 230000004761 fibrosis Effects 0.000 description 9
- 230000003449 preventive effect Effects 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000009835 boiling Methods 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 229940044551 receptor antagonist Drugs 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 8
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 7
- 206010002383 Angina Pectoris Diseases 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 208000016998 Conn syndrome Diseases 0.000 description 7
- 206010020571 Hyperaldosteronism Diseases 0.000 description 7
- 150000001204 N-oxides Chemical class 0.000 description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 description 7
- 206010008118 cerebral infarction Diseases 0.000 description 7
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 239000002395 mineralocorticoid Substances 0.000 description 7
- 208000013846 primary aldosteronism Diseases 0.000 description 7
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 6
- 208000019622 heart disease Diseases 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- POVNYOLUWDFQOZ-IMJSIDKUSA-N (4s,5s)-4,5-dimethyl-1,3,2-dioxathiolane 2,2-dioxide Chemical compound C[C@@H]1OS(=O)(=O)O[C@H]1C POVNYOLUWDFQOZ-IMJSIDKUSA-N 0.000 description 5
- 239000004215 Carbon black (E152) Substances 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 229930195733 hydrocarbon Natural products 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 235000017550 sodium carbonate Nutrition 0.000 description 5
- SAQAERNKMHATDZ-UHFFFAOYSA-N 2-bromo-1h-pyrrole Chemical compound BrC1=CC=CN1 SAQAERNKMHATDZ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 241001582429 Tetracis Species 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000004210 ether based solvent Substances 0.000 description 4
- 150000008282 halocarbons Chemical class 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- NMEAGYKSZYLEAS-UHFFFAOYSA-N 4-methylsulfonylaniline;hydrochloride Chemical compound Cl.CS(=O)(=O)C1=CC=C(N)C=C1 NMEAGYKSZYLEAS-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- MLKAVNNWGFMCSZ-UHFFFAOYSA-N methyl 5-bromo-4-methyl-1h-pyrrole-3-carboxylate Chemical compound COC(=O)C1=CNC(Br)=C1C MLKAVNNWGFMCSZ-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 2
- OYPVMVOKQBDBNY-UHFFFAOYSA-N 5-(2-chloro-4-fluorophenyl)-4-methyl-1h-pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CNC(C=2C(=CC(F)=CC=2)Cl)=C1C OYPVMVOKQBDBNY-UHFFFAOYSA-N 0.000 description 2
- AEWIRPQKEAOPHF-UHFFFAOYSA-N 5-(2-chloro-4-fluorophenyl)-4-methyl-n-(4-methylsulfonylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=CNC=1C1=CC=C(F)C=C1Cl AEWIRPQKEAOPHF-UHFFFAOYSA-N 0.000 description 2
- JGUJSROZEXOCMT-UHFFFAOYSA-N 5-[4-chloro-2-(trifluoromethyl)phenyl]-4-methyl-1h-pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CNC(C=2C(=CC(Cl)=CC=2)C(F)(F)F)=C1C JGUJSROZEXOCMT-UHFFFAOYSA-N 0.000 description 2
- WOTUGFJUDKEEBO-UHFFFAOYSA-N 5-[4-chloro-2-(trifluoromethyl)phenyl]-4-methyl-n-(4-methylsulfonylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=CNC=1C1=CC=C(Cl)C=C1C(F)(F)F WOTUGFJUDKEEBO-UHFFFAOYSA-N 0.000 description 2
- PUXQAZJYKIJZCR-UHFFFAOYSA-N 5-[4-fluoro-2-(trifluoromethyl)phenyl]-4-methyl-1h-pyrrole-3-carboxylic acid Chemical compound OC(=O)C1=CNC(C=2C(=CC(F)=CC=2)C(F)(F)F)=C1C PUXQAZJYKIJZCR-UHFFFAOYSA-N 0.000 description 2
- LKHSQHBGFOXXHO-UHFFFAOYSA-N 5-[4-fluoro-2-(trifluoromethyl)phenyl]-4-methyl-n-(4-methylsulfonylphenyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=CNC=1C1=CC=C(F)C=C1C(F)(F)F LKHSQHBGFOXXHO-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100039556 Galectin-4 Human genes 0.000 description 2
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 239000005456 alcohol based solvent Substances 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 150000001448 anilines Chemical class 0.000 description 2
- 150000001543 aryl boronic acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- KLSYTWOYEKEMDI-UHFFFAOYSA-N methyl 5-(2-chloro-4-fluorophenyl)-4-methyl-1h-pyrrole-3-carboxylate Chemical compound COC(=O)C1=CNC(C=2C(=CC(F)=CC=2)Cl)=C1C KLSYTWOYEKEMDI-UHFFFAOYSA-N 0.000 description 2
- IOWUMBHDWOTBJV-UHFFFAOYSA-N methyl 5-[4-chloro-2-(trifluoromethyl)phenyl]-4-methyl-1h-pyrrole-3-carboxylate Chemical compound COC(=O)C1=CNC(C=2C(=CC(Cl)=CC=2)C(F)(F)F)=C1C IOWUMBHDWOTBJV-UHFFFAOYSA-N 0.000 description 2
- CMVIURBCWPMHOI-UHFFFAOYSA-N methyl 5-[4-fluoro-2-(trifluoromethyl)phenyl]-4-methyl-1h-pyrrole-3-carboxylate Chemical compound COC(=O)C1=CNC(C=2C(=CC(F)=CC=2)C(F)(F)F)=C1C CMVIURBCWPMHOI-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 150000003233 pyrroles Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- XOFNMNLYGPKKOV-UHFFFAOYSA-N (2-chloro-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1Cl XOFNMNLYGPKKOV-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006013 1,1-difluoroethoxy group Chemical group 0.000 description 1
- NOSNHVJANRODGR-UHFFFAOYSA-N 1-(2-hydroxyethyl)-4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide Chemical compound CC=1C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=CN(CCO)C=1C1=CC=CC=C1C(F)(F)F NOSNHVJANRODGR-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 description 1
- POVNYOLUWDFQOZ-UHFFFAOYSA-N 4,5-dimethyl-1,3,2-dioxathiolane 2,2-dioxide Chemical compound CC1OS(=O)(=O)OC1C POVNYOLUWDFQOZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QBMZGPYCBRVTKF-UHFFFAOYSA-N 4-methyl-n-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]-1h-pyrrole-3-carboxamide Chemical compound CC=1C(C(=O)NC=2C=CC(=CC=2)S(C)(=O)=O)=CNC=1C1=CC=CC=C1C(F)(F)F QBMZGPYCBRVTKF-UHFFFAOYSA-N 0.000 description 1
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000026372 Congenital cystic kidney disease Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014664 Endocardial fibrosis Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 101000615613 Homo sapiens Mineralocorticoid receptor Proteins 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- YAPBOBGBYQQYHX-UHFFFAOYSA-N [4-chloro-2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1C(F)(F)F YAPBOBGBYQQYHX-UHFFFAOYSA-N 0.000 description 1
- SWUPLEAGZOKLNX-UHFFFAOYSA-N [4-fluoro-2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1C(F)(F)F SWUPLEAGZOKLNX-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- NFYPHBBDAHQEJU-UHFFFAOYSA-N acetonitrile;phthalic acid Chemical compound CC#N.OC(=O)C1=CC=CC=C1C(O)=O NFYPHBBDAHQEJU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004651 carbonic acid esters Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960001208 eplerenone Drugs 0.000 description 1
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000054091 human NR3C2 Human genes 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002394 mineralocorticoid antagonist Substances 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10371508P | 2008-10-08 | 2008-10-08 | |
| US61/103,715 | 2008-10-08 | ||
| PCT/US2009/059847 WO2010042622A1 (en) | 2008-10-08 | 2009-10-07 | Atropisomers of (hydroxyalkyl) pyrrole derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0920459A2 BRPI0920459A2 (pt) | 2020-08-11 |
| BRPI0920459B1 true BRPI0920459B1 (pt) | 2021-12-14 |
Family
ID=41360127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0920459-8A BRPI0920459B1 (pt) | 2008-10-08 | 2009-10-07 | Compostos antagonistas de receptor de mineralocorticoide, composição farmacêutica e método in vitro de inibição da atividade do receptor de mineralocorticoide |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8487117B2 (Direct) |
| EP (1) | EP2349997B1 (Direct) |
| JP (2) | JP5767586B2 (Direct) |
| KR (1) | KR101643285B1 (Direct) |
| CN (1) | CN102186817B (Direct) |
| AU (1) | AU2009302371B2 (Direct) |
| BR (1) | BRPI0920459B1 (Direct) |
| CA (1) | CA2736923C (Direct) |
| ES (1) | ES2547697T3 (Direct) |
| IL (1) | IL212170A (Direct) |
| TW (2) | TWI593674B (Direct) |
| WO (1) | WO2010042622A1 (Direct) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105473552B (zh) * | 2013-08-27 | 2017-11-10 | 第一三共株式会社 | 用于产生吡咯衍生物及其中间体的方法 |
| CN112707854B (zh) * | 2019-10-25 | 2022-03-15 | 年衍药业(珠海)有限公司 | 吡咯酰胺类化合物及其用途 |
| CA3213094A1 (en) * | 2021-03-30 | 2022-10-06 | Qiao ZONG | Crystalline form of pyrrole amide compound, preparation method therefor and use thereof |
| CN115784961B (zh) * | 2021-09-10 | 2026-03-31 | 上海鼎雅药物化学科技有限公司 | 埃沙西林酮及其中间体的合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8026237B2 (en) * | 2004-07-30 | 2011-09-27 | Exelixis, Inc. | Pyrrole derivatives as pharmaceutical agents |
| ES2448498T3 (es) * | 2007-04-09 | 2014-03-14 | Daiichi Sankyo Company, Limited | Atropisómero de derivado de pirrol |
-
2009
- 2009-10-07 AU AU2009302371A patent/AU2009302371B2/en not_active Ceased
- 2009-10-07 ES ES09737501.8T patent/ES2547697T3/es active Active
- 2009-10-07 BR BRPI0920459-8A patent/BRPI0920459B1/pt active IP Right Grant
- 2009-10-07 CA CA2736923A patent/CA2736923C/en active Active
- 2009-10-07 JP JP2011531140A patent/JP5767586B2/ja active Active
- 2009-10-07 WO PCT/US2009/059847 patent/WO2010042622A1/en not_active Ceased
- 2009-10-07 EP EP09737501.8A patent/EP2349997B1/en active Active
- 2009-10-07 CN CN200980139822.5A patent/CN102186817B/zh active Active
- 2009-10-07 KR KR1020117010427A patent/KR101643285B1/ko active Active
- 2009-10-07 US US13/122,147 patent/US8487117B2/en active Active
- 2009-10-08 TW TW104142529A patent/TWI593674B/zh active
- 2009-10-08 TW TW098134174A patent/TWI547479B/zh active
-
2011
- 2011-04-06 IL IL212170A patent/IL212170A/en active IP Right Grant
-
2014
- 2014-07-22 JP JP2014148858A patent/JP6121952B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201028377A (en) | 2010-08-01 |
| AU2009302371B2 (en) | 2015-02-12 |
| BRPI0920459A2 (pt) | 2020-08-11 |
| JP6121952B2 (ja) | 2017-04-26 |
| IL212170A (en) | 2016-03-31 |
| AU2009302371A1 (en) | 2010-04-15 |
| US8487117B2 (en) | 2013-07-16 |
| TWI547479B (zh) | 2016-09-01 |
| ES2547697T3 (es) | 2015-10-08 |
| EP2349997A1 (en) | 2011-08-03 |
| HK1155163A1 (zh) | 2012-05-11 |
| TW201627283A (zh) | 2016-08-01 |
| JP2012505225A (ja) | 2012-03-01 |
| KR101643285B1 (ko) | 2016-07-29 |
| EP2349997B1 (en) | 2015-08-12 |
| CA2736923C (en) | 2016-11-22 |
| IL212170A0 (en) | 2011-06-30 |
| CA2736923A1 (en) | 2010-04-15 |
| TWI593674B (zh) | 2017-08-01 |
| JP5767586B2 (ja) | 2015-08-19 |
| US20110263673A1 (en) | 2011-10-27 |
| WO2010042622A1 (en) | 2010-04-15 |
| KR20110091663A (ko) | 2011-08-12 |
| CN102186817A (zh) | 2011-09-14 |
| JP2014196365A (ja) | 2014-10-16 |
| CN102186817B (zh) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2448498T3 (es) | Atropisómero de derivado de pirrol | |
| JP7434278B2 (ja) | ラニフィブラノールの重水素化誘導体 | |
| JP6121952B2 (ja) | （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体 | |
| BRPI0920551B1 (pt) | Compostos de 1-fenilpirrol, medicamento e composição farmacêutica | |
| JP2010111657A (ja) | ピロール誘導体のアトロプ異性体を含有する医薬 | |
| WO2023016249A1 (zh) | 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法 | |
| HK1155163B (en) | Atropisomers of (hydroxyalkyl) pyrrole derivatives | |
| CN116903556A (zh) | 一种不可逆的hdac6亚型选择性抑制剂及其制备方法和应用 | |
| WO2026086905A1 (zh) | 一种作为钠通道调节剂的化合物的前药及其用途 | |
| JP2010195688A (ja) | Ｎｐｙｙ５受容体拮抗作用を有するアミド及びウレア誘導体 | |
| HK1139942B (en) | Atropisomer of pyrrole derivative | |
| HK40052014B (en) | Deuterated derivatives of lanifibranor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: EXELIXIS, INC. (US) ; DAIICHI SANKYO COMPANY, LIMITED (JP) |
|
| B25G | Requested change of headquarter approved |
Owner name: EXELIXIS, INC. (US) ; DAIICHI SANKYO COMPANY, LIMITED (JP) |
|
| B25A | Requested transfer of rights approved |
Owner name: EXELIXIS, INC. (US) |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |